UBS Raises PT on Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the Low Risk Penny Stocks to Buy Now. On March 5, UBS analyst David Dai raised the firm’s price target on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) from $2 to $4, while maintaining a Neutral rating on the stock.

​The improved price target is based on fundamental improvements in fiscal Q4 2025; however, Amtagvi acceleration remains uncertain, said the analyst in his research note. The company reported fiscal Q4 2025 earnings on February 24. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) grew its quarterly revenue by 17.74% year-over-year to $86.77 million and topped estimates by $5.76 million. The EPS for the quarter came in at negative $0.18 but stayed in line with the consensus.

​Management attributed growth to be driven by the commercialization of AMTAGVI in advanced melanoma. The drug witnessed accelerated uptake across both academic and community treatment centers. Full-year product revenue reached $264 million, driven by a 112% year-over-year increase in AMTAGVI revenue.

​Management noted that the fiscal 2026 revenue guidance will be provided in the near future.

​Iovance Biotherapeutics Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company that develops and commercializes cell therapies using autologous tumor-infiltrating lymphocytes for the treatment of metastatic melanoma and other solid tumor cancers in the US and internationally.

While we acknowledge the potential of IOVA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Disclosure: None.